by dyadic | Jul 7, 2026 | Press Releases
C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant FundingJUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a...
by dyadic | Jun 29, 2026 | Press Releases
Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein SolutionsJUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a...
by dyadic | Jun 15, 2026 | Press Releases
Company’s C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial marketsJUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) —...
by dyadic | May 28, 2026 | Press Releases
Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic’s C1 Platform Capabilities for Fast, Scalable Biologic ProductionJUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic,”...
by dyadic | May 21, 2026 | Press Releases
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology...
